Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 3/20 | 1.00 |
| ▸ | PDK4 | Q16654 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL319934 | 1.00 | PDK2 (1.00) | PDK2PDK4LMNAAKR1B1PGR | |
| SCHEMBL7134735 | 0.84 | PDK2 (0.71) | PDK2PDK4LMNAPGRKMT2A | |
| SCHEMBL9591821 | 0.83 | PDK2 (0.71) | PDK2PDK4LMNAPGRKMT2A | |
| SCHEMBL31911 | 0.80 | PDK2 (0.67) | PDK2PDK4LMNAAKR1B1KMT2A | |
| SCHEMBL29371027 | 0.80 | PDK2 (0.67) | PDK2PDK4LMNAAKR1B1KMT2A | |
| SCHEMBL10690527 | 0.80 | PDK2 (0.67) | PDK2PDK4LMNAAKR1B1KMT2A | |
| SCHEMBL2264508 | 0.78 | PDK2 (0.64) | PDK2PDK4LMNAAKR1B1KMT2A | |
| SCHEMBL2313519 | 0.78 | PDK2 (0.64) | PDK2PDK4LMNAKMT2AMEN1 | |
| SCHEMBL2264504 | 0.78 | PDK2 (0.64) | PDK2PDK4LMNAAKR1B1KMT2A | |
| SCHEMBL2266448 | 0.78 | PDK2 (0.64) | PDK2PDK4LMNAAKR1B1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118223047-A | Method for synthesizing N-Mannich alkali compound by taking methanol as carbon source under electric assistance | 天津科技大学 | 2024-06-21 | — | — | CN | claimed |
| CN-116157398-A | 2- (4- ((5- (benzo [ b ] thiophen-3-yl) -1H-tetrazol-1-yl) methyl) phenyl) -5- (difluoromethyl) -1,3, 4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC 6) for the treatment of, for example, peripheral neuropathy | 意大发马克股份公司 | 2023-05-23 | — | — | CN | claimed |
| CN-109743875-B | Inhibitors of the MENIN-MLL interaction | 生命医药有限责任公司 | 2022-04-29 | — | — | CN | claimed |
| EP-4720068-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | Beone Medicines I GmbH (CH) | 2026-04-08 | — | — | EP | disclosed |
| US-20250340546-A1 | HSD17B13 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-11-06 | — | — | US | disclosed |
| CN-116157398-B | Oxadiazole-based selective histone deacetylase 6 inhibitors | 意大发马克股份公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119330982-A | Azetidine compound and medical application thereof | 中国科学院上海药物研究所 | 2025-01-21 | — | — | CN | disclosed |
| WO-2024245430-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE, LTD. (GB) | 2024-12-05 | — | — | WO | disclosed |
| US-20240368131-A1 | OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | VENTUS THERAPEUTICS U S INC (US) | 2024-11-07 | — | — | US | disclosed |
| CN-118561823-A | 2-Alkyl-3, 3-diaryl indoline series compounds, and preparation method and application thereof | 江西师范大学 | 2024-08-30 | — | — | CN | disclosed |
| CN-118272274-B | Lactic acid bacteria starter and application thereof in preparation of blueberry corn peptide fermentation liquor | 齐齐哈尔大学 | 2024-08-09 | — | — | CN | disclosed |
| CN-117105933-A | Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity | 吉利德科学公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-112969505-B | Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity | 吉利德科学公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-4225735-A1 | PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-10 | — | — | US | disclosed |
| CN-112209866-B | Method for preparing 1-tertiary butyl-3, 3-dimethyl indoline compound | 同济大学 | 2023-06-16 | — | — | CN | disclosed |
| CN-116157398-A | 2- (4- ((5- (benzo [ b ] thiophen-3-yl) -1H-tetrazol-1-yl) methyl) phenyl) -5- (difluoromethyl) -1,3, 4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC 6) for the treatment of, for example, peripheral neuropathy | 意大发马克股份公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2023076167-A1 | INHIBITOR OF BTK AND MUTANTS THEREOF | NEWAVE PHARMACEUTICAL INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| CN-109743875-B | Inhibitors of the MENIN-MLL interaction | 生命医药有限责任公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2022076496-A1 | PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340546-A1 | HSD17B13 INHIBITORS | HSD17B3, HSD17B13, HSD17B1 | PDK2 512/4885PDK4 316/4885LMNA 3138/4885 |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | PDK2 4006/4885PDK4 4051/4885LMNA 4230/4885 |
| US-20240368131-A1 | OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF | NLRP3, NLRP1, NOD1 | PDK2 2596/4885PDK4 1684/4885LMNA 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.